Apixaban in Obese Patients

Please use landscape view or desktop screen to view the content.

Risk of Major Bleeding by BMI Category in Patients With VTE Prescribed DOACs Compared to Patients With BMI ≥25 to <30 kg/m^{2 1}

Perino 2021

Summary: In multivariable analyses, DOACs were not associated with an increased risk of major bleeding for those in higher BMI categories compared to
those in the average BMI category (≥25 to <30 kg/m²).

Outcomes*	Unadjusted^†			Adjusted^†,‡
Outcomes*	HR	95% CI	P value	HR	95% CI	P value
Major bleed
≥50 kg/m²	0.41	0.06-2.92	.37	0.49	0.07-3.51	.47
≥40 to <50 kg/m²	0.75	0.42-1.34	.33	0.76	0.42-1.37	.36
≥35 to <40 kg/m²	0.94	0.64-1.38	.74	0.98	0.66-1.45	.91
≥30 to <35 kg/m²	0.76	0.55-1.04	.09	0.78	0.57-1.08	.13
<25 kg/m²	1.34	0.99-1.81	.005	1.14	0.84-1.54	.41

1|2|3|4|5|6|7|8|9|10|11|12

*Reference BMI ≥25 to <30 kg/m².
^†Cox proportional hazards models to adjust for site.
^‡A multivariable model includes age, sex, race, antiplatelet prescription, HAS-BLED score, CCI, and all baseline comorbidities (anemia, coronary artery disease, chronic kidney disease, diabetes, heart failure, hypertension, PAD, prior MI, prior stroke, or TIA).

BMI, body mass index; CCI, Charlson comorbidity index; CI, confidence interval; DOAC, direct oral anticoagulant; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly; HR, hazard ratio; MI, myocardial infarction; PAD, peripheral artery disease; TIA, transient ischemic attack; VTE, venous thromboembolism.

Risk of Major Bleeding by BMI Category in Patients With VTE Prescribed DOACs Compared to Patients With BMI ≥25 to <30 kg/m2 1

Risk of Major Bleeding by BMI Category in Patients With VTE Prescribed DOACs Compared to Patients With BMI ≥25 to <30 kg/m^{2 1}